IP Library Granted Patent US 8,323,889
Granted Patent B2
US 8,323,889 · App. 12/140,496 · Granted Dec 4, 2012

Process for the production of an abuse-proofed solid dosage form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,323,889
App. No.
12/140,496
Granted
Dec 4, 2012
Kind
B2
Abstract

The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a synthetic or natural polymer with a breaking strength of =500 N, characterized in that a corresponding mixture is processed by melt extrusion with the assistance of a planetary-gear extruder.

Claims (13)

1. A process for the production of an abuse-proofed solid dosage form comprising (i) at least one active ingredient with potential for abuse and (ii) polyalkylene oxide (C), said at least one active ingredient with potential for abuse being selected from the group consisting of oxymorphone and the esters, ethers, amides, salts and solvates thereof, said polyalkylene oxide (C) being present at a molecular weight of from 1 million to 15 million and in an amount of at least 35% by weight, based on the weight of the dosage form, wherein said dosage form has a breaking strength of at least 500 N, and said process comprises processing a mixture comprising the at least one active ingredient with potential for abuse and the polyalkylene oxide (C) by melt extrusion with the assistance of a planetary-gear extruder into formed articles, which formed articles are optionally subjected to singulation and shaping to yield the dosage form.

2. A process according to claim 1 , wherein the polyalkylene oxide (C) is at least one polymer selected from among the group consisting of polyethylene oxides and copolymers thereof with at least one polymer selected from the group consisting of polyethylenes, polypropylenes, polyvinyl chlorides, polycarbonates, polystyrenes, and polyacrylates.

3. A process according to claim 1 , wherein the mixture additionally comprises further auxiliary substances.

4. A process according to claim 1 , wherein the planetary-gear extruder has at least three planetary spindles.

5. A process according to claim 1 , wherein the planetary-gear extruder has a feed screw and a central spindle with planetary spindles.

6. A process according to claim 1 , which further comprises heating the mixture in the planetary-gear extruder at least until the polyalkylene oxide (C) has softened, and thereafter compacting and extruding the mixture.

7. A process according to claim 1 , wherein a plastic extrudate is finally formed as a result of said melt extrusion and optionally singulated.

8. A process according to claim 1 , wherein an extrudate is formed as a result of said melt extrusion and formed into tablets.

9. A process according to claim 8 , wherein the tablets are formed with press molding with the assistance of two counter-rotating rolls with mutually opposing recesses, the construction of which recesses determines the tablet shape.

10. A process according to claim 8 , wherein the tablets are in each case formed with the assistance of a die and at least one shaping punch.

11. A process according to claim 1 , wherein the extrudate is singulated into a multiparticulate form, and optionally formed and optionally press-molded into tablets or packaged in capsules.

12. An abuse-proofed dosage form obtainable by a process according to claim 1 .

13. A method of treating pain comprising administering to a patient in need thereof an effective amount to treat pain of at least one active ingredient with potential for abuse selected from the group consisting of oxymorphone and physiologically acceptable compounds and derivatives thereof, wherein said at least one active ingredient with potential for abuse is administered to said patient in the form of a dosage form according to claim 12 .

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.. Recorded Mar 24, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032513/0255 →
GRANT OF SECURITY INTEREST IN LICENSED PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0620 →
RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 032380/0157 →
RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25456/172 Recorded Jul 12, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026577/0357 →
SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Jul 8, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026561/0978 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Dec 9, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025456/0172 →